THROMBOSIS AND HEMOSTASIS Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
نویسندگان
چکیده
1Institute for Transfusion Medicine and Immune Hematology, German Red Cross Blood Donor Service Baden-Wuerttemberg–Hessen, Clinics of the Johann Wolfgang Goethe University, Hessen, Germany; 2Children’s Hospital of Philadelphia, Philadelphia, PA; 3Hemophilia Center Frankfurt, Clinics of the Johann Wolfgang Goethe University, Hessen, Germany; and 4Institute for Biomedical Research Georg-Speyer-Haus, Frankfurt, Germany
منابع مشابه
Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
BACKGROUND Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. OBJECTIVES To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. METHODS Activity of FVa variants was studied in vitro using prothrombinase assays with purified components and in FV- and FVIII-deficient plasma using clotting and throm...
متن کاملTHROMBOSIS AND HEMOSTASIS Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
A long-acting factor VIII (FVIII) as a replacement therapy for hemophilia A would significantly improve treatment options for patients with hemophilia A. To develop a FVIII with an extended circulating half-life, but without a reduction in activity, we have engineered 23 FVIII variants with introduced surface-exposed cysteines to which a polyethylene glycol (PEG) polymer was specifically conjug...
متن کاملHEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Creation of a mouse expressing defective human factor IX
The majority of cases of human hemophilia B are the result of missense mutations in the coagulation factor IX gene and defective circulating factor IX is detectable in most patients. The available mouse factor IX knockout models of hemophilia B (FIXKO mouse) reproduce the bleeding phenotype of human hemophilia B, but because the models produce no factor IX they fail to reproduce the dominant hu...
متن کاملDesign and characterization of an APC-specific serpin for the treatment of hemophilia.
Hemophilia is a bleeding disorder caused by deficiency in factors VIII or IX, the two components of the intrinsic Xase complex. Treatment with replacement factor can lead to the development of inhibitory antibodies, requiring the use of bypassing agents such as factor VIIa and factor concentrates. An alternative approach to bypass the Xase complex is to inhibit endogenous anticoagulant activiti...
متن کاملGene targeting in hemostasis. factor XI.
Factor XI (FXI) is the zymogen of a plasma serine protease (FXIa) that contributes to hemostasis by activating factor IX (FIX). This reaction appears to be important for sustaining thrombin production after initial fibrin formation, to consolidate and protect fibrin clots from degradation by fibrinolysis. Humans with congenital FXI deficiency have a variable propensity to bleed after trauma or ...
متن کامل